333 related articles for article (PubMed ID: 31836274)
1. Efficacy of rifaximin in the different clinical scenarios of hepatic encephalopathy.
Coronel-Castillo CE; Contreras-Carmona J; Frati-Munari AC; Uribe M; Méndez-Sánchez N
Rev Gastroenterol Mex (Engl Ed); 2020; 85(1):56-68. PubMed ID: 31836274
[TBL] [Abstract][Full Text] [Related]
2. Current vision on diagnosis and comprehensive care in hepatic encephalopathy.
Higuera-de-la-Tijera F; Velarde-Ruiz Velasco JA; Raña-Garibay RH; Castro-Narro GE; Abdo-Francis JM; Moreno-Alcántar R; Pérez-Hernández JL; Torre A; Contreras-Omaña R; Cano-Contreras A; Castillo-Barradas M; Pérez-Escobar J; Aldana-Ledesma JM; Cerda-Reyes E; Fernández-Pérez NJ; Meza-Cardona J; Flores-García NC; Reyes-Bastidas M; Lira-Vera JE; García-Jiménez ES; Santana-Vargas D; Páez-Zayas VM; Chávez-Tapia NC; Márquez-Guillén E
Rev Gastroenterol Mex (Engl Ed); 2023; 88(2):155-174. PubMed ID: 37127462
[TBL] [Abstract][Full Text] [Related]
3. Overt Hepatic Encephalopathy: Current Pharmacologic Treatments and Improving Clinical Outcomes.
Rahimi RS; Brown KA; Flamm SL; Brown RS
Am J Med; 2021 Nov; 134(11):1330-1338. PubMed ID: 34242619
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.
Ahire K; Sonawale A
J Assoc Physicians India; 2017 Aug; 65(8):42-46. PubMed ID: 28799305
[TBL] [Abstract][Full Text] [Related]
5. L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial.
Jain A; Sharma BC; Mahajan B; Srivastava S; Kumar A; Sachdeva S; Sonika U; Dalal A
Hepatology; 2022 May; 75(5):1194-1203. PubMed ID: 34822189
[TBL] [Abstract][Full Text] [Related]
6. Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding.
Higuera-de-la-Tijera F; Servín-Caamaño AI; Salas-Gordillo F; Pérez-Hernández JL; Abdo-Francis JM; Camacho-Aguilera J; Alla SN; Jiménez-Ponce F
Can J Gastroenterol Hepatol; 2018; 2018():3015891. PubMed ID: 30079329
[TBL] [Abstract][Full Text] [Related]
7. Management of hepatic encephalopathy in the hospital.
Leise MD; Poterucha JJ; Kamath PS; Kim WR
Mayo Clin Proc; 2014 Feb; 89(2):241-53. PubMed ID: 24411831
[TBL] [Abstract][Full Text] [Related]
8. A Randomized Controlled Trial Comparing the Efficacy of a Combination of Rifaximin and Lactulose with Lactulose only in the Treatment of Overt Hepatic Encephalopathy.
Hasan S; Datta S; Bhattacherjee S; Banik S; Saha S; Bandyopadhyay D
J Assoc Physicians India; 2018 Jan; 66(1):32-6. PubMed ID: 30341842
[TBL] [Abstract][Full Text] [Related]
9. Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy.
Wang Z; Chu P; Wang W
Drug Des Devel Ther; 2019; 13():1-11. PubMed ID: 30587923
[TBL] [Abstract][Full Text] [Related]
10. Optimal treatment of hepatic encephalopathy.
Waghray A; Waghray N; Kanna S; Mullen K
Minerva Gastroenterol Dietol; 2014 Mar; 60(1):55-70. PubMed ID: 24632768
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the cost-effectiveness of rifaximin-α for the management of patients with hepatic encephalopathy in the United Kingdom.
Berni E; Murphy D; Whitehouse J; Conway P; Di Maggio P; Currie CJ; Poole C
Curr Med Res Opin; 2018 Nov; 34(11):2001-2008. PubMed ID: 29995455
[TBL] [Abstract][Full Text] [Related]
12. Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy.
Hayakawa Y; Tamaki N; Nakanishi H; Kurosaki M; Tanaka Y; Inada K; Ishido S; Kirino S; Yamashita K; Nobusawa T; Matsumoto H; Kakegawa T; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Kaneko S; Yasui Y; Takahashi Y; Tsuchiya K; Okamoto R; Izumi N
Intern Med; 2023 Apr; 62(7):973-978. PubMed ID: 36070941
[TBL] [Abstract][Full Text] [Related]
13. Update on the Therapeutic Management of Hepatic Encephalopathy.
Kornerup LS; Gluud LL; Vilstrup H; Dam G
Curr Gastroenterol Rep; 2018 Apr; 20(5):21. PubMed ID: 29644492
[TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis.
Huang E; Esrailian E; Spiegel BM
Aliment Pharmacol Ther; 2007 Oct; 26(8):1147-61. PubMed ID: 17894657
[TBL] [Abstract][Full Text] [Related]
15. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence.
Hudson M; Schuchmann M
Eur J Gastroenterol Hepatol; 2019 Apr; 31(4):434-450. PubMed ID: 30444745
[TBL] [Abstract][Full Text] [Related]
16. Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic Encephalopathy.
Flamm SL
Am J Med Sci; 2018 Sep; 356(3):296-303. PubMed ID: 30286824
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
Sharma BC; Sharma P; Lunia MK; Srivastava S; Goyal R; Sarin SK
Am J Gastroenterol; 2013 Sep; 108(9):1458-63. PubMed ID: 23877348
[TBL] [Abstract][Full Text] [Related]
18. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
[TBL] [Abstract][Full Text] [Related]
19. Clinical Outcomes of Oral Zinc Therapy in Hepatic Encephalopathy Treatment.
Fritz MK; Mangino AA; Hunt TV; Pitcock CT; Dugan AJ; Karri K; Yarra P
Ann Pharmacother; 2023 Aug; 57(8):899-906. PubMed ID: 36367093
[TBL] [Abstract][Full Text] [Related]
20. [Reduction of hospital stay with the use of L-ornithine L-aspartate (LOLA) in patients with hepatic encephalopathy].
Abdo-Francis JM; Pérez-Hernández JL; Hinojosa-Ruiz A; Hernández-Vásquez JR
Rev Gastroenterol Mex; 2010; 75(2):135-41. PubMed ID: 20615780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]